PMID- 28413924
OWN - NLM
STAT- MEDLINE
DCOM- 20180322
LR  - 20180322
IS  - 1743-1328 (Electronic)
IS  - 0161-6412 (Linking)
VI  - 39
IP  - 6
DP  - 2017 Jun
TI  - Erythropoietin attenuates axonal injury after middle cerebral artery occlusion in 
      mice.
PG  - 545-551
LID - 10.1080/01616412.2017.1316904 [doi]
AB  - OBJECTIVE: Erythropoietin (EPO) confers potent neuroprotection against ischemic 
      injury through a variety of mechanisms. However, the protective effect of EPO on 
      axons after cerebral ischemia in adult mice is rarely covered. The purpose of 
      this study was to investigate the potential neuroprotective effects of EPO on 
      axons in mice after cerebral ischemia. METHODS: A total of 30 adult male C57 BL/6 
      mice were treated with EPO (5000 IU/kg) or vehicle after transient middle 
      cerebral artery occlusion (MCAO). The mortality rate of each experimental group 
      was calculated. Neurological function was assessed by Rota-rod test. Frozen 
      sections from each mouse brain at 14 days after reperfusion were used to evaluate 
      the fluorescent intensity of myelin basic protein (MBP) and neurofilament 200 
      (NF-200). Immunofluorescence staining and Western blotting were used to assess 
      the protein level of beta-amyloid precursor protein (beta-APP) and glial fibrillary 
      acidic protein (GFAP), a marker of mature astrocytes. The protein levels of the 
      myelin-derived growth inhibitory proteins, neurite growth inhibitor-A (Nogo-A), 
      myelin-associated glycoprotein (MAG) and oligodendrocyte-myelin glycoprotein 
      (OMG) were also examined by Western blot after MCAO. RESULTS: The survival rate 
      of the vehicle group 14 days after cerebral ischemia-reperfusion was 50%, which 
      increased to 80% after EPO treatment at the start of reperfusion. EPO improved 
      neurobehavioral outcomes at days 3 and 7 after MCAO was compared with the vehicle 
      group (P < 0.05). Furthermore, EPO ameliorated demyelination, demonstrated by 
      upregulation of the MBP/NF-200 ratio. Meanwhile, increased levels of beta-APP, GFAP, 
      Nogo-A, and MAG after MCAO were reduced by EPO treatment (P < 0.05). CONCLUSION: 
      EPO treatment attenuates axonal injury and improves neurological function after 
      cerebral ischemia in adult mice.
FAU - Wang, Rongliang
AU  - Wang R
AD  - a Cerebrovascular Diseases Research Institute and Department of Neurology , 
      Xuanwu Hospital of Capital Medical University , Beijing , China.
AD  - b Center of Stroke , Beijing Institute for Brain Disorders , Beijing , China.
AD  - c Beijing Key Laboratory of Translational Medicine for Cerebrovascular Diseases , 
      Beijing , China.
FAU - Zhao, Haiping
AU  - Zhao H
AD  - a Cerebrovascular Diseases Research Institute and Department of Neurology , 
      Xuanwu Hospital of Capital Medical University , Beijing , China.
AD  - b Center of Stroke , Beijing Institute for Brain Disorders , Beijing , China.
AD  - c Beijing Key Laboratory of Translational Medicine for Cerebrovascular Diseases , 
      Beijing , China.
FAU - Li, Jincheng
AU  - Li J
AD  - d Department of Neurology , Zibo Central Hospital , Zibo , China.
FAU - Duan, Yunxia
AU  - Duan Y
AD  - b Center of Stroke , Beijing Institute for Brain Disorders , Beijing , China.
AD  - c Beijing Key Laboratory of Translational Medicine for Cerebrovascular Diseases , 
      Beijing , China.
FAU - Fan, Zhibin
AU  - Fan Z
AD  - a Cerebrovascular Diseases Research Institute and Department of Neurology , 
      Xuanwu Hospital of Capital Medical University , Beijing , China.
AD  - b Center of Stroke , Beijing Institute for Brain Disorders , Beijing , China.
AD  - c Beijing Key Laboratory of Translational Medicine for Cerebrovascular Diseases , 
      Beijing , China.
FAU - Tao, Zhen
AU  - Tao Z
AD  - a Cerebrovascular Diseases Research Institute and Department of Neurology , 
      Xuanwu Hospital of Capital Medical University , Beijing , China.
AD  - b Center of Stroke , Beijing Institute for Brain Disorders , Beijing , China.
AD  - c Beijing Key Laboratory of Translational Medicine for Cerebrovascular Diseases , 
      Beijing , China.
FAU - Ju, Fei
AU  - Ju F
AD  - e Internal Medicine Department , Central Hospital of Beijing Prison 
      Administration Bureau , Beijing , China.
FAU - Yan, Feng
AU  - Yan F
AD  - a Cerebrovascular Diseases Research Institute and Department of Neurology , 
      Xuanwu Hospital of Capital Medical University , Beijing , China.
AD  - b Center of Stroke , Beijing Institute for Brain Disorders , Beijing , China.
AD  - c Beijing Key Laboratory of Translational Medicine for Cerebrovascular Diseases , 
      Beijing , China.
FAU - Luo, Yumin
AU  - Luo Y
AD  - a Cerebrovascular Diseases Research Institute and Department of Neurology , 
      Xuanwu Hospital of Capital Medical University , Beijing , China.
AD  - b Center of Stroke , Beijing Institute for Brain Disorders , Beijing , China.
AD  - c Beijing Key Laboratory of Translational Medicine for Cerebrovascular Diseases , 
      Beijing , China.
LA  - eng
PT  - Journal Article
DEP - 20170416
PL  - England
TA  - Neurol Res
JT  - Neurological research
JID - 7905298
RN  - 0 (Neuroprotective Agents)
RN  - 0 (Nogo Proteins)
RN  - 11096-26-7 (Erythropoietin)
SB  - IM
MH  - Animals
MH  - Axons/drug effects/*metabolism
MH  - Disease Models, Animal
MH  - Erythropoietin/*pharmacology
MH  - Infarction, Middle Cerebral Artery/*drug therapy
MH  - Male
MH  - Mice, Inbred C57BL
MH  - Neuroprotective Agents/pharmacology
MH  - Nogo Proteins/metabolism
OTO - NOTNLM
OT  - Axonal injury
OT  - Demyelination
OT  - Erythropoietin
OT  - Neurite growth inhibitor-A
OT  - beta-amyloid precursor protein
EDAT- 2017/04/18 06:00
MHDA- 2018/03/23 06:00
CRDT- 2017/04/18 06:00
PHST- 2017/04/18 06:00 [pubmed]
PHST- 2018/03/23 06:00 [medline]
PHST- 2017/04/18 06:00 [entrez]
AID - 10.1080/01616412.2017.1316904 [doi]
PST - ppublish
SO  - Neurol Res. 2017 Jun;39(6):545-551. doi: 10.1080/01616412.2017.1316904. Epub 2017 
      Apr 16.